213 related articles for article (PubMed ID: 20354542)
21. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Mackay HJ; Billingsley K; Gallinger S; Berry S; Smith A; Yeung R; Pond GR; Croitoru M; Swanson PE; Krishnamurthi S; Siu LL
Am J Clin Oncol; 2005 Dec; 28(6):547-54. PubMed ID: 16317262
[TBL] [Abstract][Full Text] [Related]
23. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
24. [Biotherapy in colorectal cancer].
Des Guetz G
J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Pozzo C; Basso M; Cassano A; Quirino M; Schinzari G; Trigila N; Vellone M; Giuliante F; Nuzzo G; Barone C
Ann Oncol; 2004 Jun; 15(6):933-9. PubMed ID: 15151951
[TBL] [Abstract][Full Text] [Related]
26. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin: a new agent for colorectal cancer.
Pelley RJ
Curr Oncol Rep; 2001 Mar; 3(2):147-55. PubMed ID: 11177747
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Douillard JY
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S34-7. PubMed ID: 15871764
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Rahbari NN; Reissfelder C; Schulze-Bergkamen H; Jäger D; Büchler MW; Weitz J; Koch M
BMC Cancer; 2014 Mar; 14():174. PubMed ID: 24612620
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
[TBL] [Abstract][Full Text] [Related]
32. New options and old dilemmas in the treatment of patients with advanced colorectal cancer.
Punt CJ
Ann Oncol; 2004 Oct; 15(10):1453-9. PubMed ID: 15367403
[TBL] [Abstract][Full Text] [Related]
33. [Colorectal carcinoma].
Schulthess G; Kolyvanos Naumann U; Käser L; Vetter W
Praxis (Bern 1994); 2005 Nov; 94(44):1705-11; quiz 1712. PubMed ID: 16309014
[No Abstract] [Full Text] [Related]
34. Colorectal liver metastases.
Tzeng CW; Aloia TA
J Gastrointest Surg; 2013 Jan; 17(1):195-201; quiz p.201-2. PubMed ID: 23054896
[TBL] [Abstract][Full Text] [Related]
35. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Bathe OF; Ernst S; Sutherland FR; Dixon E; Butts C; Bigam D; Holland D; Porter GA; Koppel J; Dowden S
BMC Cancer; 2009 May; 9():156. PubMed ID: 19457245
[TBL] [Abstract][Full Text] [Related]
36. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
Lubezky N; Geva R; Shmueli E; Nakache R; Klausner JM; Figer A; Ben-Haim M
World J Surg; 2009 May; 33(5):1028-34. PubMed ID: 19234865
[TBL] [Abstract][Full Text] [Related]
37. Second-line therapy in colorectal cancer.
Berlin J
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):21-6. PubMed ID: 11204658
[TBL] [Abstract][Full Text] [Related]
38. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
[TBL] [Abstract][Full Text] [Related]
40. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
